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Abstract
Aneuploidy is among the most obvious differences between normal and cancer cells. However, mechanisms con-
tributing to development and maintenance of aneuploid cell growth are diverse and incompletely understood. Func-
tional genomics analyses have shown that aneuploidy in cancer cells is correlated with diffuse gene expression
signatures and aneuploidy can arise by a variety of mechanisms, including cytokinesis failures, DNA endoreplication,
and possibly through polyploid intermediate states. To identify molecular processes contributing to development of
aneuploidy, we used a cell spot microarray technique to identify genes inducing polyploidy and/or allowing mainte-
nance of polyploid cell growth in breast cancer cells. Of 5760 human genes screened, 177 were found to induce
severe DNA content alterations on prolonged transient silencing. Association with response to DNA damage stim-
ulus and DNA repair was found to be the most enriched cellular processes among the candidate genes. Functional
validation analysis of these genes highlighted GINS2 as the highest ranking candidate inducing polyploidy, accu-
mulation of endogenous DNA damage, and impairing cell proliferation on inhibition. The cell growth inhibition and
induction of polyploidy by suppression of GINS2 was verified in a panel of breast cancer cell lines. Bioinformatic
analysis of published gene expression and DNA copy number studies of clinical breast tumors suggested GINS2
to be associated with the aggressive characteristics of a subgroup of breast cancers in vivo. In addition, nuclear
GINS2 protein levels distinguished actively proliferating cancer cells suggesting potential use of GINS2 staining as
a biomarker of cell proliferation as well as a potential therapeutic target.
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Introduction
The dysregulated gene expression patterns supporting growth and
survival of cancer cells and maintenance of sustained ploidy changes
can involve various cellular processes. Genome-wide expression micro-
array studies have revealed that the biological and clinical heterogeneity
of breast cancers can be partly explained by information embedded
within complex, but ordered transcriptional architecture [1] that in-
fluences the biochemical and behavioral properties of tumors. These
profiles can be used for improved disease subtyping, patient prognosis,
and disease treatment [2]. Recent advances in the molecular profiling
of tumors have revealed a multitude of genes whose expression levels
in primary tumors correlate strongly with the probability of metastasis
and disease progression [2–4]. In particular, genes that are involved in
the cellular responses to DNA damage, cell cycle, and differentiation
have been associated with cancer initiation and metastasis [5–8]. An
important link between these processes and a driver of cancer prolifera-
tion, invasion, and metastasis is chromosomal instability. Chromo-
somal instability increases genetic variability helping cancer cells to
adapt to different environmental challenges and therapies. By acquir-
ing genomic alterations, cancer cells become independent of normal
regulatory cell processes and environmental stimuli. Changes in the
chromosomal content and gene expression signatures persist also in
cancer-derived model cell lines [9]. Excessive genetic damage is, how-
ever, detrimental, and many chemotherapeutic agents are active be-
cause of the inability of cancer cells to sustain DNA damage and
repair the genetic defects.
Mechanistically aneuploidy can arise by multiple mechanisms, such
as nondisjunction of chromosomes during mitosis, chromosomal
breakage leading to DNA loss or gain, or by generation of multi-
nucleation and polyploidy. Here, we focused on the mechanisms of
polyploidy formation and carried out a RNAi screen to identify genes
involved in the regulation of coordinated cell division and main-
tenance of ploidy level in cancer cells. We used our recently developed
cell spot microarray (CSMA) method to analyze RNAi effects causing
sustained ploidy changes in MDA-MB-231 breast cancer cells. Silenc-
ing of 177 of the 5760 human genes included in the analysis was
found to induce impaired cellular effects, causing either sustained poly-
ploidy or polyploidy with subsequent induction of apoptosis. Bioinfor-
matic comparison of clinical gene expression profiling coupled with
analysis of clinicopathologic parameters and gene copy number analy-
sis of breast cancer cell lines and primary breast tumors was then ap-
plied to study the clinical significance of the candidate genes in vivo.
DNA replication complex GINS protein 2, GINS2, was identified as
the top candidate based on both RNAi effects and clinicopathologic
associations. Silencing of GINS2 led to increased fraction of polyploid
cells and accumulation of endogenous DNA damage in the MDA-
MB-231 cells and inhibition of cell growth and viability in all subse-
quently analyzed breast cancer cell lines.
Materials and Methods
Preparation of CSMAs
Small interfering RNA (siRNA) libraries for CSMA printing were
prepared with a Hamilton STAR liquid handling robot (Hamilton
Robotics, Bonaduz, Switzerland) by mixing for each sample 5 μl of
1.67 μM siRNA aliquots in 384-well microplates with 0.8 μl of
siLentFect (Bio-Rad, Hercules, CA) transfection reagent and 0.2 μl
of OptiMEM I (Gibco, Carlsbad, CA). Solutions were incubated for
20 minutes at room temperature and mixed with 2 μl of growth
factor–reduced Matrigel (BD Biosciences, Franklin Lakes, NJ) and 2 μl
of ice-cold OptiMEM I supplemented with 65 mM sucrose, snap-
frozen at −80°C, and stored at −20°C. A prevalidated siRNA for
CD9 was used for validation of the transfection efficacy of MDA-
MB-231 cells on CSMAs (SI02777187; Qiagen, Hilden, Germany).
A Qiagen druggable genome siRNA library version 1.0 with 2 siRNA
constructs against 5760 genes was used for the primary analysis. For
validation experiments two prevalidated siRNA constructs (Qiagen)
were used to target each candidate (Table W2). Arrays were printed
on untreated polystyrene microplates with four large rectangular wells
(Nunc, Rochester, NY) using a Genetix QArray2 (Genetix Ltd, New
Milton, UK) microarray printer with 200-μm solid tip pins (Point
Technologies, Alajuela, Costa Rica). For the CSMA experiments with
MDA-MB-231 breast cancer cells, cells were grown to 80% confluence
on 10-cm culture dishes and dissociated with HyQtase (HyClone,
Logan, UT) treatment for 5 minutes. After dissociation, cells were
suspended back to the conditioned culture medium and dispersed on
the array wells as a uniform cell suspension. A total of 3 × 106 cells in
4.5 ml of medium were added to each array well and were allowed to
adhere at +37°C and 5% CO2 for 20 minutes. After adhesion, all un-
adhered cells were washed off from the well, and 4.5 ml of fresh culture
medium was added to each well. Cells were then transfected on the
arrays for 7 days for primary analysis, with medium changed after
96 hours. In the secondary analyses, cells were transfected on the arrays
for 96 hours before immunostaining and analysis.
Cell Culture and Cell Lines
HCC-1937, MCF-10A, MDA-MB-231, and T-47D used in the ex-
periments were obtained from ATCC (Rockville, MD). JIMT-1 breast
carcinoma cells were obtained from DSMZ (German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany). HCC-
1937 cells were grown in RPMI-1640 (Gibco) supplemented with
10% FBS (Gibco), 10 μg/ml penicillin and streptomycin (Sigma, St
Louis, MO), and 2 mM L-glutamine (Sigma). MCF-10A cells were
grown in mammary epithelial basal medium (Lonza, Basel, Switzerland)
supplemented with SingleQuots additives (Lonza) and 100 ng/ml chol-
era toxin. MDA-MB-231 cells were grown in low-glucose Dulbecco’s
modified Eagle medium (Gibco) supplemented with 10% FBS (Gibco),
10 μg/ml penicillin and streptomycin (Sigma), 2 mM L-glutamine
(Sigma), and 1%MEM nonessential amino acids (Sigma). JIMT-1 cells
were grown in 50:50 mixture of high-glucose Dulbecco’s modified
Eagle medium (Gibco)–RPMI-1640 (Gibco) supplemented with
10% FBS (Gibco), 10 μg/ml penicillin and streptomycin (Sigma), and
2 mM L-glutamine (Sigma). Cells were maintained in a state of loga-
rithmic growth, and experiments were performed between passages 3
and 20 after first thaw.
Bioinformatic Analysis of Expression of Candidate Genes in
Clinical Breast Cancer Samples
Analysis of clinical expression profile of the candidate genes was per-
formed with meta-analysis of a previously published gene expression
profiling of 251 human breast tumors hybridized to both Affymetrix
U133A and U133B human GeneChips ([10], GEO accession number
GSE3494) as previously described [11,12]. Briefly, data were prepro-
cessed using R (R Development core team) and the RMA method im-
plemented in the Bioconductor package affy. Affymetrix probes were
mapped directly to Ensembl gene IDs during preprocessing. Data for
genes appearing on both chip types were combined by calculating
their medians from both chips. ERBB2, Ki-67, and PCNA status was
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estimated from the expression data themselves. Tumors were classified
into defined breast cancer subtypes according to a previously described
molecular descriptor [13]. The Mann-Whitney U test was used to test
whether the medians of two category phenotypes are statistically sig-
nificantly different. Analysis of relative median expression level of
candidate genes in the GeneSapiens transcriptomics database was per-
formed as described previously [12].
Gene Copy Number Analysis
Genome-wideDNAcopy number analysis ofMDA-MB-231,MCF-7,
and T-47D cells was based on a previous analysis (GSE15477) of the
cell lines using human genome Comparative Genome Hybridization
(CGH) 44A and 44B oligo aCGH microarrays (Agilent Technologies,
Palo Alto, CA). Array-based CGH validation analysis of the T-47D cells
was performed using Agilent 244K oligonucleotide microarrays accord-
ing to the direct method of the June 2006, version 4 protocol (Agilent
Technologies). Female genomic DNA (Promega, Madison, WI) was
used as reference. Briefly, 1 μg of digested and purified sample and ref-
erence DNA was labeled with Cy5-dUTP and Cy3-dUTP (Perkin-
Elmer,Wellesley,MA), respectively, according to the protocol. Labeled
cell line and reference samples were pooled and hybridized onto an
array. After hybridization, arrays were washed and scanned with a laser
confocal scanner (Agilent Technologies). Signal intensities were ex-
tracted using the Feature Extraction software (Agilent Technologies),
and the CGH Analytics (Agilent Technologies) was used for data
analysis and visualization GEO accession no. GSE22547.
Copy number changes for GINS2 (Agilent ID: A16P20552751)
from 178 primary breast cancer cases were extracted from Hu-244A
CGH microarrays (Agilent Technologies; unpublished data). The tu-
mors are part of a cohort of 212 primary breast cancer cases sequentially
collected at Oslo University Hospital Ullevål, Norway, from 1990 to
1994 with an observation time of 12 to 16 years [14]. The samples were
profiled by standard protocol [15] without prelabeling amplification
step. Scanned microarray images were read and analyzed with
Feature Extraction v9.5 (Agilent Technologies) with protocols (CGH-
v4_95_Feb07 and CGH-v4 91 2) for aCGH preprocessing, which
included linear normalization. Data were segmented using the PCF
(Piecewise Constant Fit) algorithm [16] with settings Kmin = 5 and γ =
25. Aberrations were scored with a threshold of 0.3; gain > 0.3 and
loss < −0.3. Statistical association of copy number changes for GINS2
and survival were performed in SPSS 16.0 (SPSS, Inc, Chicago, IL).
Immunofluorescence Staining
Immunofluorescence staining of the CSMAs was performed using
standard procedures. Cells on arrays were fixed with 2% paraformal-
dehyde solution for 15 minutes and permeabilized with 0.3% Triton
X-100 in PBS for 15 minutes, and the background was blocked with
2% BSA in PBS for 1 hour before staining with primary and secondary
antibodies. Before addition of the primary antibody, the arrays were
rinsed with dH2O and air-dried. A PAP-pen (Sigma) was used to line
the arrays with a hydrophobic lining to reduce antibody/staining solu-
tion consumption. Primary antibodies forCD9 (1:250, rabbit anti-CD9;
Santa Cruz Biotechnology, Santa Cruz, CA), cleaved PARP (cPARP;
1:300, mouse anti-cPARP; Cell Signaling Technologies, Danvers,
MA), and γ-H2Ax (1:300, rabbit anti–γ-H2Ax; Abcam, Cambridge,
MA) were diluted in the blocking buffer and incubated for 60 minutes
at room temperature at 80 μl per array. Secondary labeling antibodies
goat–antimouse and donkey–antirabbit conjugated with Alexa 488
and 647 dyes (1:300; Molecular Probes, Invitrogen, Carlsbad, CA) were
diluted in blocking buffer and incubated for 60minutes at room temper-
ature. Then, 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI; Invitro-
gen) and 0.1 μM phalloidin–Alexa488 were added to secondary
antibody solution for DNA and F-actin staining. After secondary label-
ing, CSMAs plates were rinsed with dH2O, air-dried, and stored pro-
tected from light for imaging.
For immunofluorescence staining of GINS2 and Ki-67, MDA-MB-
231 cells were cultured on coverslips and stained using the same protocol
as the CSMAs. Primary antibodies for GINS2 (1:200, chicken anti-
GINS2; Sigma) and Ki-67 (1:300, rabbit anti-Ki67; Abcam) were di-
luted in 2% BSA-PBS blocking buffer and incubated for 60 minutes
at room temperature. Secondary labeling antibodies goat–anti-chicken
and donkey–anti-rabbit conjugated with Alexa488 and 647 dyes
(1:300; Molecular Probes, Invitrogen) were diluted in blocking buffer
and incubated for 60 minutes at room temperature. Then, 1 μg/ml
DAPI (Invitrogen) was added to secondary antibody solution for
DNA staining. After secondary labeling, cells were mounted with
ProLongGold mounting medium (Invitrogen). Imaging and image-
based cytometry analysis was performed with scanR microscope using
20× and 60× objectives.
In the secondary CSMA analysis, the cells were pulse labeled with 5-
ethynyl-2′-deoxyuridine (EdU) for 1 hour at +37°C (5 μM; Invitrogen)
before fixing and immunofluorescent staining. Alexa488 EdU detection
kit (Invitrogen) was used for EdU staining according to the manufac-
turer’s instructions. For the analysis, each array spot was imaged using
20× objective, and nuclear intensities of EdU, cPARP, and γ-H2Ax were
measured against the DNA counterstaining with the scanR image anal-
ysis software. To evaluate the significance of the signal distribution of
the targeting siRNAs, a z score against the mean signals, and SD of the
control samples was calculated.
Reverse Transcription–Polymerase Chain Reaction and
Western Blot Analysis
For quantitative reverse transcription–polymerase chain reaction
(qRT-PCR) analysis, the total cellular RNA was isolated using TRIzol
reagent (Invitrogen). For complementary DNA (cDNA) synthesis,
200 ng of total RNA was reverse-transcribed with the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA).
The cDNA was diluted 1:10, and TaqMan qRT-PCR analysis was
performed with an Applied Biosystems 7900HT instrument, using pri-
mers designed for GINS2 by the Universal Probe Library Assay Design
Center (Roche, Indianapolis, IN): forward 5′-TCTGGACAAGATC-
TACCTCATCG-3′ and reverse 5′-CACTTCCACGGGTAAACCA-3′.
The fluorescent TaqMan probes were obtained from Roche Human
Probe Library. Results were analyzed using SDS 2.3 and RQ manager
software (Applied Biosystems), and the relative expression of mes-
senger RNA (mRNA) was determined using GAPDH as an endoge-
nous control. The data from two separate biological experiments
with triplicate samples were combined. For Western blot analysis, ali-
quots of total cell lysates were fractionated on sodium dodecyl sulfate–
polyacrylamide gels and transferred to Whatman Protran nitrocellulose
membrane (Whatman, Inc, Piscataway, NJ). The filters were blocked
against nonspecific binding using 5% skim milk. Membranes were
probed with antibodies overnight at +4°C (GINS2, 1:500; CD9,
1:1000; Santa Cruz Biotechnology). Total protein loading was con-
firmed by probing the same filter with a specific antibody for tu-
bulin (1:5000; Abcam). Signals were revealed by incubating the filters
with secondary antibody Alexa Fluor 680 antimouse IgG (Invitrogen)
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and scanning the filters with an Odyssey Licor infrared scanner (LI-
COR Biosciences, Lincoln, NE).
Validation Experiments with siRNAs: Cell Viability Assays and
Live-Cell Imaging
In validation of target silencing and assaying the effect of GINS2
siRNAs (Qiagen SI02653056, SI02653581, SI04439757, SI04439764)
on the growth of breast cancer cells, the cells were cultured on clear-
bottom 96-well (2000 cells per well) and 12-well (2 × 105 cells per well)
plates and transfected with 10 nM siRNA constructs (Qiagen) using
siLentFect (Bio-Rad). Cell viability was assayed with CellTiter-Blue
cell viability assay (Promega). About 10 μl of CellTiter-Blue diluted
with 10 μl of OptiMEM I (Gibco) medium without supplements was
added to each 96-well containing 100 μl of medium and cells. Reagent
was incubated at +37°C for 4 hours followed with 2 hours of stabiliza-
tion at room temperature before analysis. Fluorescence signal (excita-
tion, 560 nm; emission, 590 nm) reflecting the relative number of
viable cells per well was measured with EnVision fluorescence plate
reader (Perkin-Elmer). Data from four replicate wells were combined
for analysis.
Time-lapse imaging of cells transfected on CSMAs was performed
with Incucyte HD live-cell imaging microscope using 20× objective
(Essen Instruments, Ann Arbor, MI). Images were acquired every
2 hours for 7 days.
Results
RNAi-Induced Polyploidy Assay
To characterize genes involved in the maintenance of coordinated
cell division of aneuploid cancer cells, we performed a RNAi screen
with human MDA-MB-231 breast cancer cells using our recently de-
veloped CSMA technique allowing production of high-density siRNA
reverse transfection cell microarrays. In the method, individual target-
ing siRNAs and negative control siRNAs are printed on an Society for
Biomolecular Sciences–sized microplate with a hydrophobic poly-
styrene surface in an arrayed configuration for the lipid based reverse
transfection of siRNAs to the cells [17]. To test efficacy of the MDA-
MB-231 transfection on the CSMAs before the screening, we per-
formed a Western blot and antibody-based immunofluorescent analysis
of the cells transfected on CSMAs for 48 and 72 hours, respectively,
using a prevalidated siRNA for CD9. On the basis of microscopic im-
munofluorescent quantitation of whole-cell area CD9 staining against
DNA counterstaining of the cells after 72 hours of transfection, a mean
CSMA spot level silencing efficacy of 75% in 384 random-order
printed CD9 spots was achieved in comparison to an equal number
of control siRNA spots (CD9 siRNA coefficient of variation 15.17%
vs control siRNA coefficient of variation 14.11%, P < .0001; Figure 1B).
In addition, CD9 silencing was also found to be accompanied with a
40% reduction in number of cells per spot (31 ± 12 vs 58 ± 6, P <
.0001; Figure 1B). With Western blot analysis of cells transfected
on identical arrays with 384 replicate spots (Ø 200 μm) of the CD9
siRNA and the control siRNA, more than 80% silencing efficacy was
measured with normalization against β-tubulin (Figure 1B). Verifying
the microscopy detected reduction of cell numbers on CSMA spots
after silencing of CD9, in the Western blot analysis, the total protein
amount detected by probing for tubulin was decreased by 25% after
48 hours of transfection.
For the RNAi analysis of induction of polyploidy, we focused on the
identification of sustained polyploidy phenotypes in theMDA-MB-231
cells after 7 days of transfection. MDA-MB-231 is an aneuploid cell line
with a modal chromosomal number of 54 (including 22 numerical
changes) and has multiple structurally rearranged chromosomes [9]. In
the CSMA analysis, we used a druggable genome siRNA library consist-
ing of two individual siRNA constructs targeting 5760 human genes.
Individual targeting siRNAs and negative control siRNAs were printed
on themicroplate surface in a randomized order, resulting in an arraywith
a total of 15,552 cell spots, each associated with a single siRNA or control
reagent. Cells were seeded onto the CSMA and allowed to transfect for
7 days (Figure 1A). The culture medium was changed after 4 days to
prevent cell starvation. After transfection, cells were fixed and stained
with a DNA binding dye (DAPI) and with fluorescently labeled phal-
loidin for detection of nuclear and cellular shape and size (Figure 1C ).
To analyze the array and detect polyploid cells, we used automated
fluorescence microscopy imaging of the array using 20× objective and
visual nuclear morphology–based identification of polyploid cells after
automated quantification of total cell number on the array spots. We
calculated the fraction of polyploid cells per spot (polyploid cell index,
or PCI) by dividing the number of detected polyploid cells by the total
number of cells per spot. The identified phenotypes were further clas-
sified as sustained or apoptotic polyploidy on basis of the nuclear mor-
phology (symmetric round nucleus vs fragmented nucleus; Figure 2A).
On the basis of the prevailing phenotype, the candidate genes inducing
a greater than 20% penetrance of polyploid cells per spot (PCI = 0.2)
were divided into these two categories (Figure 2A). With the threshold
of 20% polyploid cells per spot and two independent analyses of the
resulting phenotypes, silencing of 177 genes were considered positive
(3% hit rate), with 28 genes scoring with both of the used siRNAs.
On the basis of the phenotypic stratification, 134 of the candidate
genes were considered sustained polyploidy phenotypes and 43 as apop-
totic polyploidy (Table W1). The PCI threshold used was determined
so that the spontaneously occurring polyploid cell fraction within the
MDA-MB-231 cell population was clearly lower. Analysis of the mean
PCI in the group of 375 control siRNA positions was 0.022 (2.2%).
Besides automated analysis of cell numbers, a total of 15,552 compos-
ite images produced in the screen were visually inspected for the pres-
ence of polyploidy in two independent analyses.
Data on cell numbers per spot for all array positions (targeting and
control siRNAs) approximately fitted a normal distribution, but for
siRNAs inducing polyploidy, a significantly altered cell number distri-
butionwas identified (Figure 2B).On the basis of visual validation of cell
numbers in these positions, we found that in spots with a PCI ≥ 0.2, the
mean cell number distinctly decreased from 45 cells per the segmented
200-μm spot area in typical positions to a mean of 23 cells per spot.
Functional Annotation
To understand the underlying biological processes inducing poly-
ploidy in the analysis, we performedGeneOntology (GO) categorization
of the genes whose inhibition was associated with increased polyploidy
in MDA-MB-231 cells. Gene GO term enrichment analysis of the 177
genes using DAVID2008 Functional Annotation Tool [18,19], focus-
ing on associations with biological processes and cellular component,
indicated that response to DNA damage stimulus (21 genes), cell cycle
(34 genes), DNA repair, response to stress, DNA replication, and cell
cycle process were among the main (P < .0001) biological processes
linked to the polyploidy phenotypes in our cell array screen (Figure 2C
and Table W2). On basis of the cellular component associations,
nuclear part (34 genes), microtubule (12 genes), and spindle were the
most enriched terms associated with the gene products (P < .0001).
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The two different gene sets whose knockdown was leading to either
apoptotic or sustained polyploidy had similar GO term associations.
The 134 genes, whose knockdown induced sustained polyploidy,
fell into GO categories such as DNA repair (P = 3.2e−7, n = 14 genes),
cell cycle (P = 3.8e−6, n = 23), developmental process (P = 6.5e−4, n =
44), and regulation of apoptosis (P = 5.0e−3, n = 12). The 43 genes
whose silencing was correlated with apoptotic polyploid cells were
associated with GO categories such as DNA metabolic process (P =
1.2e−3, n = 9), DNA replication (P = 3.6e−3, n = 5), and cell cycle
(P = 5.7e−5, n = 11).
Validation Analysis
Supporting the current understanding that the impaired cellular
responses to DNA damage are among the most important molecular
Figure 1. CSMA RNAi analysis. (A) Schematic of procedure for cell seeding and assaying MDA-MB-231 cells on CSMAs. (B) A color
composite image of laser microarray scanned view of a CSMA with MDA-MB-231 cells cultured for 72 hours in 384 random-order
printed replicate spots of CD9 and negative control siRNA spots (F-actin = green, CD9 = red). Scale bar, 4 mm. Objective: 20× micro-
scopic image of a negative control and CD9 siRNA spot. Scale bar, 100 μm. Objective: 63× microscopic images of a negative control
and CD9 siRNA–transfected MDA-MB-231 cells stained for DNA (blue), F-actin (green), and CD9 (red). Scale bar, 10 μm. Quantification of
immunofluorescence analysis of CD9 silencing and cell numbers on CSMA spots after 72 hours of CD9 silencing. Lower panel: Immunoblot
analysis of CD9 and α-tubulin protein levels in MDA-MB-231 cells after 48 hours of siRNA knockdown on CSMAs with an equal number of
replicate spots of control siRNA or siCD9. (C) Low-resolution microarray-scanned fluorescence image of a CSMA with 3888 spots stained
for DNA (blue) and F-actin (red). Scale bar, 5 mm. Microscopic images of MDA-MB-231 cultured for 72 hours on CSMA spots demonstrate
detection of changed cell morphology and DNA content on the basis of F-actin and DNA staining. Scale bar, 100 μm.
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processes contributing to development and maintenance of aneuploidy
in cancer cells, these biological processes were also most enriched
among the identified candidate genes in our CSMA analysis. To con-
firm the primary screening results and to gain more insights to the
underlying biological processes inducing polyploidy, we performed a sec-
ondary CSMA screening of 30 of the candidate genes associated with
GO term GO:0006974 (response to DNA damage stimulus) and/or
GO:0006281 (DNA repair) (Table W3). A siRNA library with two
functionally prevalidated siRNA constructs for each target gene was
acquired for the analysis (Table W3).
To confirm the polyploidy induction by inhibition of these genes,
MDA-MB-231 cells transfected for 96 hours on the secondary CSMA
with three technical replicate spots of each siRNA and 304 replicates
of a negative control siRNA were analyzed using the same phenotypic
stratification as in the primary analysis. Of the 30 candidates, 27 scored
positive for induction polyploidy with both two siRNAs with at least
two-thirds of the analyzed siRNA replicate spots (Figure 3A). From
the candidates, DKC1 and LIG3 scored negative for induction of poly-
ploidy with all analyzed replicates and MSH4 scored positive with
one-sixth of all the siRNA replicates.
In addition to the visual phenotypic polyploidy analysis, we exam-
ined the effects of siRNA-mediated knockdown of the candidate genes
on cell proliferation, induction of apoptosis, and formation of endog-
enous DNA damage with a multiplexed high-content immunofluores-
cence assay. To evaluate the effect of candidate gene silencing on cell
proliferation, we applied a fluorescence-based EdU incorporation assay
for detection of active DNA synthesis as measure of cell proliferation.
To detect apoptotic cells, we used an antibody against cleaved PARP
to measure induction of apoptosis and an antibody against γ-H2Ax to
expose the potential roles of the genes in the maintenance of DNA
integrity (Figure 3, A and B). siRNAs against many of the candidate
genes (16/30) significantly (z score < −2) altered the proliferation of
Figure 2. Analysis of polyploidy induction in MDA-MB-231 cells. (A) Images of representative nuclear phenotypes used for stratification
of identified polyploid cell phenotype. Round, smooth polyploid cells were considered sustained polyploidy, and fragmented nucleus
containing cells were considered apoptotic polyploid cells. Images of MDA-MB-231 cells after 7 days of siRNA knockdown on KIF12 and
AZGP1 siRNA spots. Positions that gave an elevated polyploid cell index (PCI ≥ 0.2) from the primary screen were divided into catego-
ries of sustained (KIF12) or apoptotic (AZGP1) polyploidy phenotypes. (B) A line graph of cell number distribution across all siRNA spots
on the CSMA (blue) and siRNA hits inducing polyploidy (red). A distinct reduction of cell number on spots was associated with the
induced polyploidy phenotypes. (C) Gene ontology analysis of the candidate genes. Number of genes associated with the enriched
GO categories and significance of enrichment (−log2 P value). Threshold of significance is P = .01.
882 RNAi Induced Polyploidy in Breast Cancer Rantala et al. Neoplasia Vol. 12, No. 11, 2010
the cells as measured with the decrease in the EdU incorporation com-
pared with the control siRNA. Inhibition of multiple genes from the list
also showed significant functional defects in the other assays; 12 of
30 genes were associated with induction of apoptosis (cPARP staining
z score > 2) and 11 of 30 of the candidates affected maintenance of
DNA integrity of the cells (γ-H2Ax formation z score > 2). In summary,
5 of the 30 genes scored with both two siRNAs in all the four assays,
and 20 in two or more assays (Figure 3B). Thus, we concluded that
our gene list is highly enriched with genes that affect the maintenance
of ploidy and participate in cellular processes such as the DNA damage
responses or DNA repair mechanisms contributing to the active cell
growth of aneuploid cancer cells.
Clinical Significance
To study gene expression patterns of the validated polyploidy-inducing
genes in clinical breast cancers and to evaluate the correlation between
the gene expression data and clinicopathologic profiles in breast
cancer samples, we applied meta-analysis of the genes included in
the validation experiments in a previously published breast cancer gene
expression analysis [10]. Transcript profiles of 251 primary breast
tumors were assessed in comparison with clinicopathologic variables:
TP53 mutation, Ki-67, PCNA, ERBB2, estrogen receptor, proges-
terone receptor, and lymph node status; tumor grade; and patient sur-
vival (Figure W1). In addition, tumors were divided into previously
Figure 3. Functional validation of a subset of primary screening candidates. (A) Representative magnified images of polyploid pheno-
types induced by the candidate gene knockdowns. Cells were stained for DNA (blue), γ-H2Ax (red), cleaved PARP (magenta), and EdU
(green) for analysis of nuclear morphology, maintenance of DNA integrity, induction of apoptosis, and cell proliferation, respectively. (B)
Summary of the assay results: polyploidy induction, EdU incorporation (cell proliferation), induction of apoptosis, and γ-H2Ax assay.
Candidate genes scored in each assay with both used siRNAs are marked in red.
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defined cancer subtypes: normal, luminal A, luminal B, basal type, and
ERBB2-positive [16].
By using unsupervised hierarchical clustering of gene expression data
of the candidate genes, a subgroup of the basal-type tumors associated
with the aggressive clinicopathologic characteristics formed a separate
cluster from the rest. The most variably expressed genes distinguish-
ing the aggressive (basal) type of the tumors, included 33% (10/30) of
the genes: PCNA, BARD1, LIG1, MCM3, DKC1, TYMS, GINS2,
POLB, RNF14, and RAD50 (Figure 4). Many of the genes highly ex-
pressed in these tumors have been previously associated with breast
cancer and shown to play a role in cell cycle and cell proliferation,
such as BARD1, LIG1, MCM3, and PCNA. However, also a less well-
characterized candidate gene, GINS2 was included among the gene
set displaying the highest association with the aggressive characteristics
of the analyzed breast cancers.
Effect of GINS2 on Cell Proliferation and Cell
Cycle Progression
GINS2 was among the identified 28 double siRNA hits inducing a
sustained polyploidy phenotype in the primary analysis. In the second-
ary validation experiments, GINS2 was found to have a significant effect
on cell proliferation, survival, and maintenance of genomic integrity in
addition to the induction of polyploidy. Within the bioinformatics pro-
filing, GINS2 was identified to associate with the clinicopathologic
characteristics for aggressive basal-type breast cancers and in analysis
of the GeneSapiens database [12]; it showed an elevated expression
(≥three-fold, P = .008, t test = 3.59, N = 768) in most breast cancer
samples in comparison to normal breast tissues. Moreover, GINS2 is
located at chromosomal region 16q24, which has been previously iden-
tified to be frequently upregulated in clinical breast cancers [20]. We
validated the GINS2 mRNA down-regulation in response to RNAi
Figure 4. In silico transcriptomics analysis of the RNAi hits in clinical breast cancers. Unsupervised hierarchical clustering of the expres-
sion level of the 30 candidate primary RNAi hits included in the validation experiments in 251 breast tumors. Each cell in the cluster
shows the log2 expression ratio for the particular gene in separate tumor samples divided by the median expression of that gene in all
samples. Red indicates expression above the median; green, below the median. Upper panel: tumor-type classification of each sample.
Lower panel: sample status for clinicopathologic parameters: high ERBB2 expression, high Ki-67 expression, high PCNA expression,
lymph node positivity, presence of p53 mutation, tumor grade, PgR positivity (black bars), and patient survival.
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for both two siRNAs used in the primary screen and the two additional
siRNA constructs used for validation screening in MDA-MB-231 cells
by means of qRT-PCR. In addition, Western blot analysis of cells trans-
fected on CSMAs for 5 and 7 days (Figure W2) was used to verify the
endured silencing efficacy on CSMA spots. In addition to the verified
75% GINS2 protein level inhibition, a reduction of up to 48% (7 days
of transfection) in cell numbers on the CSMAs was detected as decrease
in the measured total protein levels based on probing for tubulin. We
then compared the mRNA expression level of GINS2 in 15 breast
cancer cell lines (Figure W2). From the analyzed cell lines, T-47D
cells displayed the highest expression level for GINS2. Results from
aCGH analysis of the corresponding cell line indicated that T-47D
cells have a heterozygous amplification of GINS2 locus, providing a
direct mechanism for the up-regulation through increased DNA copy
number (Figure W2). In addition, amplification of GINS2 locus was
found on five additional breast cancer cell lines: LY2, BT-20, HCC-
1937, HCC-1954, and MDA-MB-468 [16].
To confirm the CSMA results, we compared the GINS2 RNAi ef-
fect in four breast cancer cell lines, namely, MDA-MB-231, T-47D,
HCC-1937, and JIMT-1, and in a nonmalignant breast epithelial cell
line MCF-10A (Figure 5A). Reduced cell viability was confirmed using
an enzymatic cell viability assay of cells transfected for 120 hours (with
two of the validated GINS2 siRNAs), followed by with image-based
cytometry analysis of cell cycle effects. Cell viability assays and the
automated microscopic image analysis revealed a drastic reduction in
the number of cells in response to GINS2 inhibition (Figure 5A). Cell
cycle analysis of the cells revealed the decrease in the number of cells at
G1-S phases and the increase in the G2-M and G0/sub-G1 phases and
polyploid cell fraction (Figure W3). To further clarify the effect of
GINS2 knockdown on cellular morphology and cell cycle, we exam-
ined MDA-MB-231 cells transfected for 7 days on GINS2 CSMA
spots using time-lapse microscopy. A distinct formation of polyploid
cells and apoptotic cells was detected on GINS2 inhibition, whereas
in control position, cells retained a tight active cell growth through
the time lapse (Figure 5B).
Clinical Significance of GINS2
To investigate the biological and clinicopathologic significance of
the GINS2 copy number levels in breast carcinogenesis and possible
association with clinical outcome, we compared the copy number
status of GINS2 in an ongoing analysis of clinical primary breast tu-
mors. In previously published gene copy number analyses of clinical
Figure 5. Functional profiling of GINS2. (A) Images of MDA-MB-231, JIMT-1, T-47D, HCC-1937, and MCF-10A cells transfected with
GINS2 and negative control siRNA for 120 hours and stained with a DNA binding dye (DAPI). Image-based cytometry analysis and
an enzymatic cell viability assay were used to confirm the growth-inhibitory effects of GINS2 inhibition. Error bars indicate SD of two
replicate transfections with two siRNA constructs. (B) Time-lapse microscopic image series of MDA-MB-231 cells transfected on CSMA
spots for 7 days with GINS2 and control siRNA. Scale bar, 100 μm. (C) Immunofluorescence staining of GINS2 and Ki-67 in MDA-MB-231
cells with 60× magnification. Scale bar, 10 μm. (D) Kaplan-Meier survival plot for disease-specific survival of 178 primary breast cancer
samples, classified according to GINS2 copy number status.
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breast cancers, the chromosomal region 16q24 has been identified as
frequently lost in human breast tumors [21] but amplified and highly
expressed in a subgroup of breast tumors [20]. Within comparison
of the aCGH profiles of 178 tumors included in the mined analysis,
6 (3.4%) of 178 tumors showed copy number gain of GINS2, whereas
47 (26.4%) of 178 tumors had lost the same region (Figure W5). Patients
with a tumor that had gained a copy of GINS2 had a significant
poorer survival than the rest (P = .02) using Kaplan-Meier estimates
and log-rank comparisons (Figure 5D). Data showed a trend that
copy number gain of GINS2 was associated with high grade as mea-
sured by Kruskal-Wallis test (P = .57).
To examine the subcellular localization of endogenous GINS2 pro-
tein in cancer cells, we performed immunocytochemical analysis of
MDA-MB-231 cells using a polyclonal chicken antibody against
GINS2 (Figure W4). GINS2 was not detected in the nucleus and only
weakly around the nuclear membrane in cytoplasm during G0-G1.
From G2 to M phases, GINS2 was detected abundantly surrounding
the chromatin during anaphase to telophase (Figure 5C ). Polyploid
cells detected within the parental MDA-MB-231 population stained
also strongly positive for GINS2 in the given cell cycle phases.
The distinct staining of actively proliferating cells with GINS2 anti-
body suggested that GINS2 could potentially be used as a biomarker
to determine the growth fraction of a given cancer cell population. To
evaluate whether GINS2 staining is comparable with currently used
proliferation markers, we performed dual staining of MDA-MB-231
cells for Ki-67 and GINS2. Nuclear staining pattern of the two proteins
had a significant correlation coefficient (r = 0.84). The only difference
between the staining profiles for these two proteins was the staining of
G1 cells for Ki-67 and not for GINS2 (Figure W6A). Because staining
of cells not in the active cell cycle phases has been considered as a weak-
ness for clinical use of Ki-67, our results indicate that GINS2 could
possibly serve as a better marker for cells destined for cell division
(G2-M) and not detecting nonproliferating cells (G0-G1).
To evaluate the correlation of these two genes in clinical cancers,
we compared the coexpression pattern of Ki-67 and GINS2 in the
GeneSapiens database in 3767 gene expression analyses representing
Figure 5. (continued).
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40 different cancer types. The mRNA coexpression correlation across
all the samples was r = 0.627 (P = .01; Figure W6B), indicating a gen-
eral role for GINS2 in the proliferation of several different cancer types.
Discussion
Aneuploidy and chromosomal instability are common conditions for
most epithelial cancer cells, but the relationships between cellular
functions allowing growth and survival of aneuploid cells are not
clear. Moreover, it is not completely understood whether there is a
ploidy-sensing checkpoint in eukaryotic cells and whether cell divi-
sion of aneuploid cells requires variable expression of specified genes.
To address this question, we used RNA interference analysis to iden-
tify genes affecting ploidy regulation of cancer cells, followed by GO
categorization and in silico transcriptomics analysis to identify genes
and cellular processes associated with the induction of polyploidy in
breast cancer cells.
A collective molecular portrait descriptive of numerical chromo-
somal heterogeneity in cancer cells has been described to include
up-regulation of genes that are associated with increased cell motility
and migration, epithelial-mesenchymal transition, and cell cycle pro-
cesses. Genes whose expression has been shown to correlate negatively
with DNA content heterogeneity in cancer cells on the other hand
have been associated with, for example, nucleic acid metabolism, reg-
ulation of transcription, DNA replication, response to DNA damage
stimulus, DNA repair, chromosome organization, and DNA replica-
tion initiation [22]. In this study, GO analysis of the distribution of
177 genes identified to functionally correlate with increased polyploidy
on silencing indicated an association with highly similar functional
categories. DNA damage stimulus, cell cycle processes, DNA repair,
response to stress, and DNA replication were the main biological pro-
cesses associated with the genes increasing the numerical heterogeneity
of the chromosomal content. Moreover, within the identified gene list,
several genes previously associated with chromosomal heterogeneity
and polyploidy were identified. This supports the already-existing as-
sumptions that a compromised expression of genes related to cell cycle
processes, DNA damage response, DNA replication, and chromosome
condensation is associated with a higher level of chromosomal instabil-
ity in cancer cells [23–27].
GINS2
GINS2 (GINS complex subunit 2 [Psf2 homolog]) is a member of
the tetrameric complex termed GINS, composed of GINS1, GINS2,
GINS3, and GINS4, which most likely serves as the replicative helicase,
unwinding duplex DNA ahead of moving replication forks [28–30]. In
studies on mice and yeast, the GINS complex has been shown to asso-
ciate with the minichromosome maintenance (MCM) 2 to 7 complex
and with CDC45, and this complex (CDC45-MCM-2-7-GINS) regu-
lates both the initiation and the progression of DNA replication [31–
33]. Later, the GINS complex has been shown to be involved in DNA
replication in humans as well [34–38]. However, recent studies sug-
gest that GINS1/2 is also associated with response to replication and
DNA damage stress [39–41].
Several recent reports have suggested a role for GINS components
in cancer cells. For example, GINS components were found to be
overexpressed in aggressive melanoma [41], and GINS1 was identified
as an estrogen-regulated target in MCF-7 human breast carcinoma
cells [42]. As it has been reported that DNA replication–associated
proteins have diverse functions in different cells, for example, in deter-
mining centrosome copy numbers, in different phases of development
and disease avoidance, GINS has been suggested to have a function in
cell division, more precisely in choromosome segregation [43]; how-
ever, the role of its components in mammalian cells is not yet clear.
In this study, we found a high level of GINS2 expression in human
breast cancers and several breast carcinoma cell lines. We showed also
that GINS2 locus is amplified in T-47D breast cancer cell line and
a subgroup of clinical breast tumors. Our comparative analysis of dif-
ferent cell types showed that GINS2 is more highly expressed in cancer
cells than in nonmalignant breast epithelial cells. Moreover, GINS2
knockdown resulted in growth inhibition and induction of polyploidy
in breast cancer cells by the suppression of M-phase progression, indi-
cating that GINS2 impacts, in addition to DNA replication initiation
essential for S-phase progression (in GINS complex), cell division, and
probably chromosome segregation in human breast carcinoma cells.
Because several prereplicative complex proteins and cell division–
related proteins are overexpressed in cancer and reported as useful tumor
markers [44,45], we compared the GINS2 mRNA and protein expres-
sion with Ki-67 proliferation marker expression. On the basis of the
findings, we suggest that GINS2 is a putative biomarker for diagnosis
and analysis of progression in breast cancer as well as in several other
cancers. As prereplicative complex proteins have also been suggested to
have significant therapeutic value [44,46–48], GINS2 might also have
use as a drug target because the RNAi results indicate that its inhibition
reduces cell proliferation.
In summary, this study provides novel insights into the genetic tar-
gets involved in the maintenance of sustained ploidy and causal con-
sequences of the loss-of-function of these genes. Our results can be
used as a starting point for formation of hypotheses on events that
may impact primary tumor development and suggest regulatory cell
cycle components that could be on the basis for dysregulation of cell
cycle checkpoints leading to increased gains and losses of chromosomes
in cancer cells. The results also provide a foundation for investigating
the causative relationships of the identified candidate molecules and
the ploidy phenotype, cancer molecular markers, as well as gene ex-
pression signatures of clinical cancers.
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Table W1. Top 177 Genes Inducing Polyploidy in MDA-MB-231 Cells When Inhibited with RNAi.
Gene Name Description siRNA IDs Multinucleated Apoptotic
ADAM29 ADAM metallopeptidase domain 29 Q003485 1
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1
motif, 9
Q004438 1
ALS2 Amyotrophic lateral sclerosis 2 (juvenile) Q004524 1
ANXA5 Annexin A5 Q007210 1
APOC1 Apolipoprotein C-I Q007215 1
AQP3 Aquaporin 3 (Gill blood group) Q000150 | Q018226 1
ARTN Artemin Q002910 1
ASL Argininosuccinate lyase Q007240 | Q025316 1
ATRN Attractin Q002734 1
ATXN3 Ataxin 3 Q001569 1
AZGP1 alpha-2-Glycoprotein 1, zinc binding Q007258 | Q025334 1
AZIN1 Antizyme inhibitor 1 Q004137 1
BACE2 beta-Site APP-cleaving enzyme 2 Q003749 1
BARD1 BRCA1-associated RING domain 1 Q000228 1
BDH2 3-Hydroxybutyrate dehydrogenase, type 2 Q004418 1
BECN1 Beclin 1 (coiled-coil, myosin-like BCL2 interacting protein) Q002795 1
BLVRA Biliverdin reductase A Q007268 1
BSCL2 Bernardinelli-Seip congenital lipodystrophy 2 (seipin) Q003844 1
BTNL9 Butyrophilin-like 9 Q005311 1
CAV1 Caveolin 1, caveolae protein, 22 kDa Q000350 1
CCL22 Chemokine (C-C motif ) ligand 22 Q002184 1
CCNL2 Cyclin L2 Q004818 1
CCT6A Chaperonin containing TCP1, subunit 6A (zeta 1) Q007310 1
CDC23 Cell division cycle 23 homolog (Saccharomyces cerevisiae) Q002800 1
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) Q000439 1
CHRNA5 Cholinergic receptor, nicotinic, alpha 5 Q000476 1
CLCA2 Chloride channel, calcium-activated, family member 2 Q003092 1
CLDN4 Claudin 4 Q000544 1
CLN3 Ceroid-lipofuscinosis, neuronal 3, juvenile (Batten,
Spielmeyer-Vogt disease)
Q000506 1
CRY2 Cryptochrome 2 (photolyase-like) Q000566 1
CTSD Cathepsin D Q000596 1
CXADR Coxsackie virus and adenovirus receptor Q000607 1
DAD1 Defender against cell death 1 Q000648 1
DCC Deleted in colorectal carcinoma Q000658 1
DCLRE1C DNA cross link repair 1C (PSO2 homolog, S. cerevisiae) Q004633 1
DCXR Dicarbonyl/L-xylulose reductase Q004055 1
DDIT3 DNA damage–inducible transcript 3 Q000669 1
DIO1 Deiodinase, iodothyronine, type I Q000688 1
DKC1 Dyskeratosis congenita 1, dyskerin Q000691 1
DMC1 DMC1 dosage suppressor of mck1 homolog, meiosis-specific
homologous recombination (yeast)
Q003505 1
EED Embryonic ectoderm development Q002810 1
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 Q000746 1
EIF2C1 Eukaryotic translation initiation factor 2C, 1 Q003840 1
ENTPD6 Ectonucleoside triphosphate diphosphohydrolase 6
(putative function)
Q007314 1
EPRS Glutamyl-prolyl-tRNA synthetase Q000788 1
EVI2A Ecotropic viral integration site 2A Q000812 | Q018888 1
FANCD2 Fanconi anemia, complementation group D2 Q000836 | Q018912 1
FANCE Fanconi anemia, complementation group E Q000837 1
FBN1 Fibrillin 1 Q000848 1
FEM1B Fem-1 homolog b (Caenorhabditis elegans) Q003223 1
FKBP2 FK506 binding protein 2, 13 kDa Q000878 1
FLOT2 Flotillin 2 Q000890 1
FMO3 Flavin-containing monooxygenase 3 Q000892 | Q018968 1
FOXK2 Forkhead box K2 Q001283 1
FTL Ferritin, light polypeptide Q000916 1
FZR1 Fizzy/cell division cycle 20–related 1 (Drosophila) Q004092 1
GANAB Glucosidase, alpha; neutral AB Q003617 1
GDF3 Growth differentiation factor 3 Q003070 1
GDF9 Growth differentiation factor 9 Q000972 1
GGH Gamma-glutamyl hydrolase (conjugase,
folylpolygammaglutamyl hydrolase)
Q002855 1
GINS2 GINS complex subunit 2 (Psf 2 homolog) Q004146 | Q022222 1
GNG11 Guanine nucleotide binding protein (G protein), gamma 11 Q001032 | Q019108 1
GPC4 Glypican 4 Q000858 1
GPD2 Glycerol-3-phosphate dehydrogenase 2 (mitochondrial) Q001044 1
GRIA2 Glutamate receptor, ionotropic, AMPA 2 Q001061 1
GRIK3 Glutamate receptor, ionotropic, kainate 3 Q001071 1
GSN Gelsolin (amyloidosis, Finnish type) Q001086 1
HDAC3 Histone deacetylase 3 Q002860 1
Table W1. (continued )
Gene Name Description siRNA IDs Multinucleated Apoptotic
HDAC4 Histone deacetylase 4 Q003117 | Q021193 1
HDAC6 Histone deacetylase 6 Q003185 1
HERC3 Hect domain and RLD 3 Q002885 | Q020961 1
HERC6 Hect domain and RLD 6 Q004275 1
HGFAC HGF activator Q001138 1
HIP1 Huntingtin interacting protein 1 Q001141 | Q019217 1
HNF4G Hepatocyte nuclear factor 4, gamma Q001159 1
HNMT Histamine N -methyltransferase Q001160 1
HSD11B1L Hydroxysteroid (11-beta) dehydrogenase 1-like Q005625 1
HSD17B12 Hydroxysteroid (17-beta) dehydrogenase 12 Q004044 1
HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4 Q001185 1
HTRA2 HtrA serine peptidase 2 Q003914 1
HUS1 HUS1 checkpoint homolog (Schizosaccharomyces pombe) Q001195 1
IGF2R Insulin-like growth factor 2 receptor Q001234 1
IL8 Interleukin 8 Q001262 1
IMPG1 Interphotoreceptor matrix proteoglycan 1 Q001288 1
INCENP Inner centromere protein antigens 135/155 kDa Q001289 | Q019365 1
INDO Indoleamine-pyrrole 2,3 dioxygenase Q001290 1
IQGAP3 IQ motif containing GTPase-activating protein 3 Q005193 1
ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
VLA-3 receptor)
Q001316 1
ITGB2 Integrin, beta 2 (complement component 3 receptors 3 and
4 subunit)
Q001328 1
ITPR3 Inositol 1,4,5-triphosphate receptor, type 3 Q001338 1
JAG2 Jagged 2 Q001340 1
KCNS3 Potassium voltage-gated channel, delayed-rectifier,
subfamily S, member 3
Q001398 1
KIF12 Kinesin family member 12 Q005086 | Q023162 1
KIF13A Kinesin family member 13A Q004587 | Q022663 1
KIF15 Kinesin family member 15 Q004433 1
KIF22 Kinesin family member 22 Q001416 1
KIF23 Kinesin family member 23 Q003039 1
KIF5C Kinesin family member 5C Q001404 1
KIFC1 Kinesin family member C1 Q001414 1
KNTC1 Kinetochore-associated 1 Q003108 1
KTN1 Kinectin 1 (kinesin receptor) Q001424 1
LAMA5 Laminin, alpha 5 Q001429 1
LIG1 Ligase I, DNA, ATP-dependent Q001453 | Q019529 1
LIG3 Ligase III, DNA, ATP-dependent Q001454 1
LRP2 Low-density lipoprotein-related protein 2 Q001477 1
LRRN2 Leucine-rich repeat neuronal 2 Q003324 1
MARS Methionyl-tRNA synthetase Q001522 1
MCM2 Minichromosome maintenance complex component 2 Q001532 1
MCTS1 Malignant T-cell–amplified sequence 1 Q003927 1
MED24 Mediator complex subunit 24 Q003137 | Q021213 1
MICB MHC class I polypeptide-related sequence B Q001562 1
MLLT4 Myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 4
Q001576 1
MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) Q001583 | Q019659 1
MNAT1 Ménage à trois homolog 1, cyclin H assembly factor
(Xenopus laevis)
Q001597 1
MRAS Muscle RAS oncogene homolog Q003557 1
MSH4 MutS homolog 4 (Escherichia coli) Q001612 1
MSTN Myostatin Q000971 1
MTR 5-Methyltetrahydrofolate-homocysteine methyltransferase Q001624 1
MTUS1 Mitochondrial tumor suppressor 1 Q004489 1
MUC1 Mucin 1, cell surface–associated Q001626 | Q019702 1
NEDD4 Neural precursor cell expressed, developmentally
downregulated 4
Q001672 1
NEDD4L Neural precursor cell expressed, developmentally
downregulated 4-like
Q003639 1
NPC1L1 NPC1 (Niemann-Pick disease, type C1, gene)-like 1 Q003953 1
NPC2 Niemann-Pick disease, type C2 Q003358 1
NUDT9 Nudix (nucleoside diphosphate linked moiety X)-type
motif 9
Q004173 1
P4HB Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline
4-hydroxylase), beta polypeptide
Q001757 1
PAQR4 Progestin and adipoQ receptor family member IV Q005170 1
PCMT1 Protein-L-isoaspartate (D-aspartate) O-methyltransferase Q001786 1
PCNA Proliferating cell nuclear antigen Q001787 | Q019863 1
PHF11 PHD finger protein 11 Q004041 1
PHF12 PHD finger protein 12 Q004517 1
PMAIP1 Phorbol-12-myristate-13-acetate–induced protein 1 Q001889 1
Table W1. (continued )
Gene Name Description siRNA IDs Multinucleated Apoptotic
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) Q001893 1
PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) Q001895 1
POLB Polymerase (DNA-directed), beta Q001902 1
PPIL5 Peptidylprolyl isomerase (cyclophilin)-like 5 Q005158 1
PSCD3 Pleckstrin homology, Sec7 and coiled-coil domains 3 Q002967 1
PSMC4 Proteasome (prosome, macropain) 26S subunit, ATPase, 4 Q001977 1
PTGES3 Prostaglandin E synthase 3 Q003397 1
PYGO2 Pygopus homolog 2 (Drosophila) Q005012 1
RAB28 RAB28, member RAS oncogene family Q002993 1
RAB40B RAB40B, member RAS oncogene family Q003457 1
RAB4A RAB4A, member RAS oncogene family Q002014 1
RAB8A RAB8A, member RAS oncogene family Q001544 1
RAB9A RAB9A, member RAS oncogene family Q002994 1
RAC1 Ras-related C3 botulinum toxin substrate 1 (rho family, small
GTP binding protein Rac1)
Q002024 | Q020100 1
RAD50 RAD50 homolog (S. cerevisiae) Q003221 1
RANBP5 RAN binding protein 5 Q001420 | Q019496 1
RAPGEFL1 Rap guanine nucleotide exchange factor (GEF)-like 1 Q004059 | Q022135 1
RBL2 Retinoblastoma-like 2 (p130) Q002067 1
RERG RAS-like, estrogen-regulated, growth inhibitor Q004966 | Q023042 1
RNF14 Ring finger protein 14 Q003080 | Q021156 1
RNF7 Ring finger protein 7 Q003084 1
RRM2B Ribonucleotide reductase M2 B (TP53-inducible) Q003992 1
RSF1 Remodeling and spacing factor 1 Q004167 1
SIRT6 Sirtuin (silent mating type information regulation 2 homolog)
6 (S. cerevisiae)
Q004130 1
SLC9A3R1 Solute carrier family 9 (sodium/hydrogen exchanger),
member 3 regulator 1
Q002995 | Q021071 1
SMAD7 SMAD family member 7 Q001509 1
SMUG1 Single-strand selective monofunctional uracil-DNA
glycosylase 1
Q003700 1
SNX6 Sorting nexin 6 Q004556 1
SOX4 SRY (sex-determining region Y)-box 4 Q002305 1
SPATA20 Spermatogenesis-associated 20 Q004656 1
SRPX2 Sushi-repeat-containing protein, X-linked 2 Q003898 1
TAP2 Transporter 2, ATP-binding cassette, subfamily B (MDR/TAP) Q002369 1
TFDP1 Transcription factor Dp-1 Q002410 1
TGFB1I1 Transforming growth factor beta 1-induced transcript 1 Q002420 1
TMEM30A Transmembrane protein 30A Q004351 1
TNN Tenascin N Q004582 1
TRPM4 Transient receptor potential cation channel, subfamily M,
member 4
Q004249 1
TUBG2 Tubulin, gamma 2 Q003884 | Q021960 1
TXN Thioredoxin Q002530 1
TYMS Thymidylate synthetase Q002532 | Q020608 1
UNC13B Unc-13 homolog B (C. elegans) Q003337 1
WDHD1 WD repeat and HMG-box DNA binding protein 1 Q003510 | Q021586 1
WFS1 Wolfram syndrome 1 (wolframin) Q002594 1
VWF Von Willebrand factor Q002590 1
YEATS4 YEATS domain containing 4 Q002676 1
Table W2. GO Categories Associated with RNAi Hit Genes Inducing Polyploidy.
Category GO Term Count P Benjamini
GOTERM_BP_ALL Response to DNA damage stimulus 21 3.7e−10 1.9e−06
GOTERM_BP_ALL Response to endogenous stimulus 23 4.7e−10 8.3e−07
GOTERM_BP_ALL Cell cycle 34 4.7e−10 1.2e−06
GOTERM_BP_ALL DNA repair 19 7.2e−10 9.5e−07
GOTERM_BP_ALL Response to stress 36 4.1e−09 4.3e−06
GOTERM_BP_ALL DNA metabolic process 31 1.2e−08 0.000011
GOTERM_BP_ALL Cell cycle process 28 3.7e−08 0.000028
GOTERM_BP_ALL DNA replication 14 3.5e−06 0.002
GOTERM_BP_ALL M phase 14 .000015 0.0074
GOTERM_BP_ALL Negative regulation of cellular process 29 .000034 0.015
GOTERM_BP_ALL Cell cycle phase 15 .000035 0.014
GOTERM_BP_ALL Regulation of progression through cell cycle 18 .000061 0.023
GOTERM_BP_ALL Regulation of cell cycle 18 .000065 0.023
GOTERM_BP_ALL Negative regulation of biological process 29 .000071 0.023
GOTERM_BP_ALL Microtubule-based movement 8 .00022 0.066
GOTERM_BP_ALL Localization 55 .00023 0.066
GOTERM_BP_ALL Chromosome organization and biogenesis 14 .00038 0.099
GOTERM_BP_ALL Biological regulation 79 .00047 0.12
GOTERM_BP_ALL Cytoskeleton-dependent intracellular transport 8 .00057 0.13
GOTERM_BP_ALL Regulation of cellular process 69 .00059 0.13
GOTERM_BP_ALL Microtubule-based process 10 .00068 0.14
GOTERM_BP_ALL Mitotic cell cycle 12 .00072 0.15
GOTERM_BP_ALL Mitosis 10 .00086 0.16
GOTERM_BP_ALL M phase of mitotic cell cycle 10 .00091 0.17
GOTERM_BP_ALL Developmental process 54 .00095 0.17
GOTERM_BP_ALL Meiotic recombination 4 .0011 0.18
GOTERM_BP_ALL DNA-dependent DNA replication 7 .0013 0.21
GOTERM_BP_ALL Regulation of biological process 71 .0017 0.26
GOTERM_BP_ALL Regulation of apoptosis 15 .0023 0.31
GOTERM_BP_ALL Regulation of programmed cell death 15 .0025 0.33
GOTERM_BP_ALL Meiosis I 4 .0041 0.47
GOTERM_BP_ALL Cytoskeleton organization and biogenesis 14 .005 0.53
GOTERM_BP_ALL Establishment of localization 45 .0053 0.54
GOTERM_BP_ALL DNA recombination 7 .0062 0.57
GOTERM_BP_ALL Localization of cell 12 .0064 0.58
GOTERM_BP_ALL Cell motility 12 .0064 0.58
GOTERM_BP_ALL Establishment of cellular localization 19 .0074 0.61
GOTERM_BP_ALL Regulation of biological quality 19 .0074 0.61
GOTERM_BP_ALL Amino acid and derivative metabolic process 11 .0081 0.62
GOTERM_BP_ALL Transport 43 .0083 0.62
GOTERM_BP_ALL Anatomical structure development 36 .0088 0.63
GOTERM_BP_ALL Death 18 .0094 0.65
GOTERM_BP_ALL Cell death 18 .0094 0.65
GOTERM_BP_ALL Cell migration 9 .0096 0.65
GOTERM_BP_ALL Cellular localization 19 .0097 0.64
GOTERM_CC_ALL Nuclear part 29 .000004 0.0017
GOTERM_CC_ALL Microtubule 12 .000031 0.009
GOTERM_CC_ALL Intracellular organelle part 60 .000031 0.0067
GOTERM_CC_ALL Organelle part 60 .000034 0.0059
GOTERM_CC_ALL Macromolecular complex 48 .000059 0.0085
GOTERM_CC_ALL Spindle 7 .00016 0.019
GOTERM_CC_ALL Nucleoplasm 15 .00066 0.069
GOTERM_CC_ALL Microtubule cytoskeleton 13 .0011 0.098
GOTERM_CC_ALL Nuclear lumen 17 .0015 0.12
GOTERM_CC_ALL Organelle lumen 21 .0016 0.12
GOTERM_CC_ALL Membrane-enclosed lumen 21 .0016 0.12
GOTERM_CC_ALL Microtubule associated complex 7 .0018 0.11
GOTERM_CC_ALL Endoplasmic reticulum part 14 .0019 0.11
GOTERM_CC_ALL Endoplasmic reticulum 19 .0023 0.12
GOTERM_CC_ALL Cytoplasmic membrane-bound vesicle 11 .003 0.15
GOTERM_CC_ALL Membrane-bound vesicle 11 .0034 0.16
GOTERM_CC_ALL Cytoplasmic vesicle 12 .0038 0.17
GOTERM_CC_ALL Vesicle 12 .0045 0.19
GOTERM_CC_ALL Nucleoplasm part 12 .005 0.19
GOTERM_CC_ALL Intracellular membrane-bound organelle 92 .0056 0.2
GOTERM_CC_ALL Endoplasmic reticulum membrane 12 .0056 0.19
GOTERM_CC_ALL Membrane-bound organelle 92 .0057 0.19
GOTERM_CC_ALL Nuclear envelope-endoplasmic reticulum network 12 .0065 0.2
GOTERM_CC_ALL Intracellular organelle 102 .0098 0.28
Table W3. Genes and siRNA IDs of Candidate Targets Included in the Secondary CSMA Analysis.
Gene Name ID siRNA_A ID siRNA_B
BARD1 SI00299383 SI02664354
CDC23 SI02653112 SI02653413
CRY2 SI00354473 SI00354480
DCLRE1C SI00133945 SI02645286
DDIT3 SI00059535 SI00059528
DKC1 SI00364581 SI00364602
DMC1 SI00094374 SI00094367
FANCD2 SI00145306 SI00145292
GINS2 SI02653056 SI00131404
HDAC3 SI00057323 SI02653581
HDAC4 SI00083958 SI00057316
HDAC6 SI02757769 SI00083951
HUS1 SI02664837 SI02663808
LIG1 SI02757482 SI02633449
LIG3 SI02663549 SI02663542
MCM3 SI02664872 SI02757489
MNAT1 SI00037716 SI02664879
MSH4 SI00037877 SI00037723
PCNA SI02653357 SI02628598
PMS1 SI00011347 SI02653287
PMS2 SI03115049 SI00011333
POLB SI00041398 SI00011375
PSMC4 SI00301469 SI02663605
RAD50 SI02653826 SI02665208
RNF14 SI00062258 SI02653742
RRM2B SI02664977 SI00062244
RSF1 SI00117005 SI02664984
SIRT6 SI02777698 SI00116991
SMUG1 SI00104706 SI00116592
TYMS SI00021609 SI00104699
Figure W1. Clinicopathologic significance of polyploidy-inducing RNAi hit genes. The median expression level distribution of the can-
didate genes was assessed for correlation with 13 different clinicopathologic parameters. ***P < .001.
Figure W2. Target verification of GINS2. (A) qRT-PCR analysis of GINS2 transcript levels after knockdown with four distinct siRNAs in
MDA-MB-231 cells. Error bars indicate the SE for three qPCR measurements. (B) Immunoblot analysis of GINS2 and α-tubulin protein
levels after 5 and 7 days of siRNA knockdown on CSMA in MDA-MB-231 cells. (C) The expression profile of GINS2 mRNA in 14 different
breast cancer cell lines and nonmalignant breast epithelial cells. Log2 Affymetric scale. (D) Array-based CGH data showing amplification
of GINS2 loci (chromosomal region at 16q24.1) in T-47D breast cancer cells.
Figure W2. (continued).
Figure W3. Image based quantification of cell cycle distribution of the analyzed cell lines after GINS2 inhibition.
Figure W4. Comparison of GINS2 antibody specificity. Specificity of the GINS2 antibody was evaluated with cells transfected with a Cy3-
labeled control siRNA and a validated siRNA for GINS2. A significant association of siRNA uptake and GINS2 protein level inhibition
was verified.
Figure W5. Copy number changes from GINS2 on 178 breast cancer tumors. Of 178 patients, 47 (26.4%) show loss (<−0.3) of GINS2,
whereas 6 (3.4%) show gain (>0.3).
Figure W6. GINS2 protein and mRNA expression pattern. (A) Correlation of nuclear GINS2 and Ki-67 protein staining of MDA-MB-231 cells.
(B) mRNA coexpression pattern of GINS2 and MKI67 in 40 different cancer types analyzed from GeneSapiens gene expression database.
